Skip to main content
  • Clariant Logo
  • Share
  • Contact
  • en - US
  • Translate
  • Contrast
  • Search
  • Products & Industries
  • Sustainability
  • Company
  • Media
  • Investors
  • Careers
  • Events
Close
Search
Close
SDS & Document Finder
result(s)
All Results
Close
Facebook Twitter LinkedIn E-Mail WhatsApp More Options
Close
Close
The translation will be performed automatically using AI. Please double-check important facts and statements.
Close
Clariant International
  • Products & Industries
  • Sustainability
  • Company
  • Media
  • Investors
  • Careers
  • Events
Home / Products & Industries / Products / VitiPure Meglumine LEX
Products
Summarize
Meglumine

VitiPure Meglumine LEX

Edition Date :
February 06, 2026

VitiPure Meglumine LEX improves the solubility and bioavailability of APIs. Meglumine is a multi-talented functional excipient which is used as a counter-ion to form a salt with the API, or as a standard excipient to modify the pH to enhance the API solubility and stability. Traditionally, Meglumine is used as a counter-ion in contrast media. Applications include oral solid, and liquid formulations. And, widely used in sensitive formulations where low bioburden and low endotoxin grade is required.

Ask a Question Get a quote

Product Information

Benefits
  • Manufactured according to IPEC GMP
  • Complies to EP and USP
  • Low Endotoxin grade is suitable for sensitive applications
  • Control of TAMC, TYMC, objectionable bacteria
  • Control of elemental impurities per ICH Q3D, according to sensitive applications limits
  • In depth analysis of individual nitrosamines and risk assessment
  • Excellent solubility and bioavailability enhancement agent
  • Alternative to sodium as counter-ion
Product details
Chemical Name
  • Meglumine
Product Function
  • Solublizers
  • Neutralizer

VitiPure Meglumine LEX is used as a counter-ion in contrast media, as a buffering agent, and solubility enhancer of mildly acidic APIs.

Marketed solid formulations with meglumine include APIs such as: Telmisartan, Hydrochlorothiazide, Repaglinide, Amlodipine besylate, Lansoprazole, Rosuvastatin calcium, Esomeprazole magnesium trihydrate, Amlodipine, Ezetimibe etc.

Marketed liquid sensitive formulations with meglumine include APIs such as: Gadopentetate dimeglumine, Gadoterate meglumine, Meloxicam, Gadoteric acid, Delafloxacin meglumine, Fosaprepitant dimeglumine etc.

Ph.Eur: Megluminum; USP: Meglumine

IPEC GMP Pharma Grade

India

Clariant India Limited; Telangana 502313, India

25kg with double PE bags as inner packaging and plastic drum as external packaging; Sample size 0.5kg

24 months

Documentation

Download File

Close

Login Required

close
Log in or register to ClariHub for our full set of product documentation and more resources.
Create Account
Login

Authorization required

close
You do not have the required permissions to access the protected files related to this product. If you would like to get access, please do not hesitate to contact us.
Log in or register to ClariHub for our full set of product documentation and more resources.
Create Account Login

Related products (AI generated)

{{title}}
{{description}}
more
{{title}}
{{description}}
more
{{title}}
{{description}}
more
{{title}}
{{description}}
more
We could not find any related items.

Related resources (AI generated)

{{localizedTemplateName}}
{{title}}
{{description}}
more
{{localizedTemplateName}}
{{title}}
{{description}}
more
{{localizedTemplateName}}
{{title}}
{{description}}
more
{{localizedTemplateName}}
{{title}}
{{description}}
more
We could not find any related items.
Clariant International
          Clariant International
          We at Clariant are aware of our responsibility. Our purpose »Greater chemistry – between people and planet« describes the role we can play in the world if we align our thinking and all future decisions with it.
          Social
          • Imprint
          • Terms of Use
          • Data protection and privacy
          • General Terms and Conditions of Sale and Purchase
          Copyright © Clariant 2026. All rights reserved.

          Page summary

          close
          Summarization in progress
          The page summary is generated by AI